Skip to content

Fidelis Pharmaceuticals

Committed to providing high-quality animal welfare solutions

Fidelis Pharmaceuticals, Inc., offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs.

Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor:

  • Company headquarters is located in New Jersey.
  • Ethiqa XR is manufactured in Pennsylvania.
  • Supply chain sources and manufacturing sites and operations are in full compliance with current Good Manufacturing Practices (cGMPs) regulated by the FDA.
  • Dedicated to providing products that are indexed by the FDA.

The Fidelis Pharmaceuticals Team of Experts

Our leadership team possesses a wealth of experience in developing innovative, effective pharmaceutical solutions for veterinary medicine.

The Fidelis team applies specialized product development and manufacturing expertise to formulate reliable, cGMP-quality products uniquely suited to meet veterinary needs.

Michael Wells

Chairman and Chief Executive Officer
Michael Wells serves as the Executive Chairman for Fidelis Pharmaceuticals. He has had a long and distinguished career as an entrepreneur and an investor in start-up healthcare companies. In addition to his role at Fidelis, he is the founding Managing Director of Princeton Biopharma Capital Partners, a firm he created in 2010 for the purpose of providing growth capital to pharmaceutical and medical device companies. Prior to creating this company, he was the founder and CEO of Aton Pharma, a pharmaceutical company focused on rare diseases. For his part in creating and growing this company, he was named an Ernst & Young Entrepreneur of the Year in 2009, and in 2010 the company was acquired by Valeant Pharmaceuticals for $330 million. Michael has played a role in the formation of five companies and frequently mentors aspiring entrepreneurs. His career began at Merck & Co., where he held a range of sales and marketing positions over eight years. Michael earned Bachelor of Science and Master of Science degrees from the University of Pittsburgh, in addition to an MBA from The Wharton School. He serves on the Fidelis Board of Directors, as well as those of Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He is a Trustee at the University of Pittsburgh.

Barry Levinson, PhD

Co-Founder, Chief Operating Officer

Barry Levinson, PhD, serves as Chief Operating Officer with Fidelis Pharmaceuticals. Dr. Levinson has over 35 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. He previously served as VP Business Development at Valeant Pharma (now Bausch Health) and was a founding employee, VP Business Development and Chief Scientific Officer at Aton Pharma. At Aton, he identified and acquired several key products and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded R&D programs to develop these new indications. Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, a life sciences consulting firm, and prior to that was at consulting firm CPP Advisors (now Apeiron Partners), and the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the decade prior, Barry held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals). He began his corporate career at biotech startup Ecogen, where he founded its Protein Biochemistry Group, and served as the company’s Radiation Safety Officer.

Dr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his Bachelor of Arts, with highest honors, in Biochemistry from Princeton University. He serves on the Fidelis Board of Directors as well as that of Covis Pharmaceuticals, and is a Managing Director of Princeton Biopharma Capital Partners.

Steven Leary, DVM

Chief Medical Officer

Steven Leary, DVM, DACLAM, serves as Chief Medical Officer with Fidelis Pharmaceuticals. He received his DVM from Iowa State University and postdoctoral training in laboratory animal medicine and comparative pathology from Johns Hopkins University. Dr. Leary has 40 years’ experience, including serving as director at the University of Alabama at Birmingham and Washington University in St. Louis. He served on the AAALAC Council, as president of ACLAM, and as chair of the AVMA Animal Welfare Committee and Panels on Euthanasia, Humane Slaughter, and Depopulation. He is past recipient of the ISU Stange Award, Charles River Prize, and AALAS Griffin and Nathan R. Brewer awards.

Fidelis Pharmaceuticals Delivers Unique and Innovative Veterinary Pharmaceuticals to Address Unmet Animal Health Needs

Leaders in Long-Acting Pain Management

Fidelis Pharmaceuticals, Inc. stands ready to acquire, develop and market pharmaceutical formulations for human and veterinary medicine. Please contact a member of our team with any comments or questions.

Fidelis Pharmaceuticals, Inc.
675 Highway One, Suite B113  |  North Brunswick, New Jersey 08902
Phone: 833-ETHIQAXR (833-384-4729)

©2022 Fidelis Pharmaceuticals, Inc.